Pancreatic Cancer

15 competing products in clinical development for Pancreatic Cancer.

Pipeline by Phase

Phase 13

Phase 27

Phase 34

Approved1

All Products (15)

Product	Company	Stage	Status	Hype
Setidegrasib + Oxaliplatin + Leucovorin + Irinotecan + fluorouracil + liposomal irinotecan + Placebo	Astellas Pharma	Phase 3	Recruiting	47
Dalteparin	Eisai	Approved	Completed	43
exatecan mesylate + gemcitabine hydrochloride	Daiichi Sankyo	Phase 3	Completed	40
Tarceva (erlotinib HCl, OSI-774)	Astellas Pharma	Phase 3	Completed	40
fluorouracil + Irofulven	Eisai	Phase 3	Completed	40
zolbetuximab + nab-paclitaxel + gemcitabine	Astellas Pharma	Phase 2	Active	39
pemetrexed	Eli Lilly	Phase 2	Completed	35
mFOLFIRINOX + Ramucirumab	Eli Lilly	Phase 2	Completed	35
CS-1008 (humanized anti-DR5 antibody) + gemcitabine	Daiichi Sankyo	Phase 2	Completed	35
exatecan mesylate	Daiichi Sankyo	Phase 2	Completed	35
AGS-1C4D4 + gemcitabine	Astellas Pharma	Phase 2	Completed	35
erlotinib hydrochloride + gemcitabine hydrochloride	Astellas Pharma	Phase 2	Completed	35
Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4	Eli Lilly	Phase 1	Completed	29
erlotinib hydrochloride + gemcitabine hydrochloride	Astellas Pharma	Phase 1	Completed	29
Enzalutamide + Gemcitabine + Nab-paclitaxel	Astellas Pharma	Phase 1	Completed	29